|
|
NEWS |
 |
'Big Pharma' must plan ahead as patent expiries stimulate generics growth
Recent figures show that the global generics market grew by 20% in 2005 - three times the amount by which the pharma sector grew, and four times the growth of patented drugs. In fact, Cygnus predicts continued growth for the sector in the next five years, forecasting a CAGR of 13.62% for 2006-2010.
Analysts have identified the patent expiries of some of the pharmaceutical industry's biggest brands as the main catalyst for success for the generics sector. Datamonitor has warned that drugs worth almost $140 billion in sales will come off patent by 2016. This may be considered a conservative estimate. Elsewhere, experts predict that patents for branded pharmaceuticals with sales of over $100 billion will expire by 2010.
In fact, the imminent 2007 patent expiries of blockbusters Zyrtec (Pfizer) and Imigran (GSK)alone will bring generic competition to products that between them generated sales of over $2.5 billion in 2006. This follows hard on the heels of the 2006 expiries of blockbusters such as Zocor (Merck), Pravachol (BMS) and Zoloft (Pfizer), whose combined sales were in excess of $11 billion.
To view the rest of this news story, please click here.
|
FREE CONFERENCE DELEGATE PLACES! |
|
NeuroDrug 2007
CNS disorders: what the future holds for drugs and therapies
23-25 Oct 2007, The Royal Garden Hotel, London, UK
Report Buyer are giving away 10 free passes to the NeuroDrug 2007 conference. This offer is limited to biotech companies and pharmaceutical manufacturers only! If you would like to take up this free offer, please email press@reportbuyer.com
NeuroDrug 2007 focuses on drug discovery and development across the CNS sector. NeuroDrug will cover key neurological disorders such as epilepsy and chronic pain, neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease and psychiatric conditions such as depression, schizophrenia and anxiety disorders.
The huge gaps in drug development for CNS disorders are best addressed through scientific and industrial partnerships. NeuroDrug 2007 is the leading event to meet with industry peers, learn about new targets and advance your understanding of latest techniques and business strategies. This is an event not to be missed.
To view the conference site, please click here.
|
FEATURED REPORT |
|
Global Generics
Global Generics industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.
Scope
- Contains an executive summary and data on value, volume and/or segmentation
- Provides textual analysis of the industry's recent performance and future prospects
- Incorporates in-depth five forces competitive environment analysis and scorecards
- Includes a five-year forecast of the industry
- The leading companies are profiled with supporting key financial metrics
- Supported by the key macroeconomic and demographic data affecting the market
Read more...
|
NEW LAUNCHES |
|
Global Smoking Cessation Market Analysis & Forecasts
Preparing For The First Blockbuster
This report examines key smoking cessation markets internationally. In this report each one of these disease areas is examined in terms of market growth and revenue. Plus we examine how current and new drug treatments will take hold in each market, plus which companies will succeed in each market.
Read more...
Nutraceutical Ingredients
Innovation Strategies of Makers,Growth Opportunities and U.S. Outlook
This report covers key players and trends in the U.S. market for nutraceutical and functional ingredients. Section by section, the report contains:
- Overview of the U.S. ingredients industry and key players, including a general perspective on licensing and distribution structure.
- Detailed profiles of 11 companies and their ingredients portfolios, with emphasis on health benefits, production volume and consumption trends.
- Competitive mapping of ingredients companies and their strategies for differentiation in a crowded marketplace.
- Table summaries and comparisons of the 11 companies, with analysis of the ingredients functional food and beverage roadmap.
- Appendix listing of additional U.S. and/or multinational companies with innovative ingredients.
Read more...
Cancer Vaccine Developments to 2013
Who are the players and products in the race to launch? This report critically assesses the candidates in their wider market context, providing a complete review of the market and its likely development to 2013. The launch of Sanofi Pasteur MSD's Gardasil and GSK's Cervarix has propelled cancer vaccines from research obscurity to a key area of commercial and clinical interest. But can the sector capitalise on these gains and really fulfil its promise?
Read more...
Pharmaceutical Outsourcing in Drug Discovery and Development
Contract Research Opportunity in India
The report provides an overview of the buyer scenario and an in-depth analysis of the Indian vendor space along with profiles of major industry players. The report is designed to help:
- Pharma companies looking to outsource/offshore
- Global pharmaceutical companies to gain understanding of the Indian vendor space
- Outsourcing consultants to evaluate and compare the offerings of vendors
- Potential vendors to assess opportunities
- Contract research vendors to assess their competitive environment
- Venture capital companies looking for investment opportunities
- Researchers looking for detailed information on Contract Research Offshoring
This study is based on secondary data as well as extensive interviews with key people at various contract research organizations (captive as well as third-party) in India.
Read more...
|
FREE REPORT |
|
Blockbuster Drugs 2006: Executive Overview
Quickly review the top 10 world's best selling pharmaceutical products in 2006 with this free report.
Each blockbuster drug has the following detail:
- Target / Mechanism of Action
- Class of Compound
- Company Therapeutic
- Area
- Indication 1st approval
- 2006 sales (mln) vs. previous year (%)
To download and read the rest of this free report, please click here.
|
|
